Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f91a008c1bac8eecbe244c861c32d762 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
filingDate |
2013-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2018-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6871a9b414daa5731e91065441865a0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b47f94f0f3f272843ebc81a24877b34d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f28c3b09077ea528b4f5976acf4a249 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5226acd63a9f248b6f00b7b39498125a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d21c01df8c6f04a4df489b0ec2538f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5f95ca49681bd4d418139d2060d150b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e3a7064f54899ef61b1cc3f84745e14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24f853d932049db516a8805711575779 |
publicationDate |
2018-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
RU-2656153-C1 |
titleOfInvention |
Alpha-enolase specific antibodies and methods of uses in cancer therapy |
abstract |
FIELD: chemistry. n SUBSTANCE: present invention refers to immunology. Disclosed is an anti-alpha-enolase (ENO1) antibody, as well as its scFv and Fab fragment. Also described is a pharmaceutical composition for treating a malignant neoplasm; as well as a method for diagnosing a malignant neoplasm and a method for inhibiting the invasion of a malignant neoplasm. Antibody of the invention is capable of binding to peptides comprising the amino acid sequence FDQDDWGAWQKFTA and / or KRIAKAVNEKS of the human protein ENO1 and has a suitable binding activity (binding affinity is about 10 -10 mol/l). n EFFECT: present invention can find further application in the therapy and diagnosis of diseases associated with ENO1. n 8 cl, 17 dwg, 3 tbl, 17 ex |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2761662-C2 |
priorityDate |
2013-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |